source
- Combination of danvatirsen and pembrolizumab fails to boost response in first-line metastatic head-and-neck cancerThe phase II PEMDA-HN trial evaluated adding the STAT3 antisense oligonucleotide danvatirsen to pembrolizumab in patients with untreated recurrent or metastatic head and neck squamous cell carcinom…
- Sacituzumab Govitecan-Trastuzumab Combo Shows Low Response in HER2-Positive Metastatic Breast Cancer After T-DXDThe phase 2 SATEEN trial evaluated sacituzumab govitecan combined with trastuzumab in patients with HER2-positive metastatic breast cancer who had progressed on T-DXD. The study enrolled 27 evalua…onclive · 4mo agoNegative readoutNegative